Ovarian carcinoma diagnosis: The clinical impact of 15 years of change

British Journal of Cancer

Volumn 115, Issue 8, 2016, Pages 993-999

  Kommoss, Stefan ^a   Gilks, C Blake ^b   Du Bois, Andreas ^c   Kommoss, Friedrich ^b,d  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c KLINIKEN ESSEN MITTE   (Germany)

^d Institute of Pathology   (Germany)

Author keywords

case review; diagnosis; gynaecopathology; histotype; ovarian carcinoma; pathology; prognosis; translational research

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PACLITAXEL; PROTEIN P16; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; COLLOID CARCINOMA; ENDOMETRIOID CARCINOMA; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); OVARY CARCINOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSITIONAL CELL CARCINOMA; TRANSLATIONAL RESEARCH; TUMOR DIFFERENTIATION; ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; CARCINOMA; CARCINOMA, ENDOMETRIOID; CLASSIFICATION; COMPARATIVE STUDY; GENETICS; KAPLAN MEIER METHOD; MORTALITY; OBSERVER VARIATION; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; REPRODUCIBILITY; RETROSPECTIVE STUDY; TUMOR SUPPRESSOR GENE; WORLD HEALTH ORGANIZATION;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; BIOMARKERS, TUMOR; CARCINOMA; CARCINOMA, ENDOMETRIOID; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; GENES, P16; GENES, RETINOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MULTICENTER STUDIES AS TOPIC; OBSERVER VARIATION; OVARIAN NEOPLASMS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TRANSLATIONAL MEDICAL RESEARCH; WORLD HEALTH ORGANIZATION;

EID: 84988384035     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.273     Document Type: Article

References (27)

1. Acs G, Pasha T, Zhang PJ. (2004). WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol 23(2): 110-118
2. Anglesio M, Kommoss S, Tolcher M, Clarke B, Galletta L, Porter H, Damaraju S, Fereday S, Winterhoff B, Kalloger S, Senz J, Yang W, Steed H, Allo G, Ferguson S, Shaw P, Teoman A, Garcia J, Schoolmeester J, Bakkum-Gamez J, Tinker A, Bowtell D, Huntsman D, Gilks C, McAlpine J. (2012). Molecular characterization of mucinous ovarian tumors supports a stratified treatment approach with HER2 targeting in 18% of carcinomas. J Pathol 229(1): 111-120
3. Clarke B, Tinker AV, Lee CH, Subramanian S, Van De Rijn M, Turbin D, Kalloger S, Han G, Ceballos K, Cadungog MG, Huntsman DG, Coukos G, Gilks CB. (2009). Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 22(3): 393-402
4. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J. Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study G. (2003). A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17): 1320-1329
5. Fletcher C. (2013). Diagnostic Histopathology of Tumors. 4th edn (Churchill Livingston: Philadelphia, PA, USA
6. Fountain J, Trimble E, Birrer MJ. (2006). Recommendations of the 2005 Ovarian Cancer State of the Science Meeting. Gynecol Oncol 103 (2 Suppl 1): S26
7. International Federation of Obstetrics and Gynecology. (1971). Classification and staging of malignant tumors in the female pelvis. Acta Obstet Gynecol Scand 50: 1-7
8. Kobel M, Bak J, Bertelsen BI, Carpen O, Grove A, Hansen ES, Levin Jakobsen AM, Lidang M, Masback A, Tolf A, Gilks CB, Carlson JW. (2014). Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology 64(7): 1004-1013
9. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D. (2008). Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5(12): e232
10. Kommoss F, Kommoss S, Schmidt D, Trunk MJ, Pfisterer J, du Bois A. (2005). Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel. Gynecol Oncol 97(1): 195-199
11. Kommoss S, du Bois A, Ridder R, Trunk MJ, Schmidt D, Pfisterer J, Kommoss F. (2007). Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Br J Cancer 96(2): 306-313
12. Kurman RJ, Carcangiu ML, Herrington CS, Young RH (eds). (2014). WHO Classification of Tumours of Female Reproductive Organs. 4th edn. IARC Press: Lyon, France
13. Kurman RJ, Shih Ie M. (2011). Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 42(7): 918-931
14. Mackenzie R, Talhouk A, Eshragh S, Lau S, Cheung D, Chow C, Le N, Cook LS, Wilkinson N, McDermott J, Singh N, Kommoss F, Pfisterer J, Huntsman DG, Kobel M, Kommoss S, Gilks CB, Anglesio MS. (2015). Morphologic and molecular characteristics of mixed epithelial ovarian cancers. Am J Surg Pathol 39(11): 1548-1557
15. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG. (2004). Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28(4): 496-504
16. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, Mulligan AM, Couch FJ, Engel C, McGuffog L, Healey S, Sinilnikova OM, Southey MC, Terry MB, Goldgar D, O'Malley F, John EM, Janavicius R, Tihomirova L, Hansen TV, Nielsen FC, Osorio A, Stavropoulou A, Benitez J, Manoukian S, Peissel B, Barile M, Volorio S, Pasini B, Dolcetti R, Putignano AL, Ottini L, Radice P, Hamann U, RashidMU, Hogervorst FB, Kriege M, Van Der Luijt RB, Hebon, Peock S, Frost D, Evans DG, Brewer C, Walker L, Rogers MT, Side LE, Houghton C. EMBRACEWeaver J, Godwin AK, Schmutzler RK, Wappenschmidt B, Meindl A, Kast K, Arnold N, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Varon-Mateeva R, Schonbuchner I, Gevensleben H, Stoppa-Lyonnet D, Belotti M, Barjhoux L, Collaborators GS, Isaacs C, Peshkin BN, Caldes T, De la Hoya M, Canadas C, Heikkinen T, Heikkila P, Aittomaki K, Blanco I, Lazaro C, Brunet J, Agnarsson BA, Arason A, Barkardottir RB, Dumont M, Simard J, Montagna M, Agata S, D'Andrea E, Yan M, Fox S, kConFab I, Rebbeck TR, Rubinstein W, Tung N, Garber JE, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Szabo C, Offit K, Sakr R, Gaudet MM, Singer CF, Tea MK, Rappaport C, Mai PL, Greene MH, Sokolenko A, Imyanitov E, Toland AE, Senter L, Sweet K, Thomassen M, Gerdes AM, Kruse T, Caligo M, Aretini P, Rantala J, von Wachenfeld A, Henriksson K, Collaborators S-B, Steele L, Neuhausen SL, Nussbaum R, BeattieM, Odunsi K, Sucheston L, Gayther SA, Nathanson K, Gross J, Walsh C, Karlan B, Chenevix-Trench G, Easton DF, Antoniou AC. Consortium of Investigators of Modifiers of B. (2012). Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomark Prev 21(1): 134-147
17. McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Kobel M, Kalloger SE, Swenerton KD, Huntsman DG, Gilks CB, Miller DM. (2009). HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 9: 433
18. McCluggage WG. (2011). Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 43(5): 420-432
19. Poulsen H, Taylor C, Sobin L. (1975). Histological Typing of Female Genital Tract Tumours. World Health Organization: Geneva, Switzerland
20. Prat J. (2012). New insights into ovarian cancer pathology. Ann Oncol 23 (Suppl 10): x111-x117
21. Prat J. (2012). Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch 460(3): 237-249
22. Schrader KA, Hurlburt J, Kalloger SE, Hansford S, Young S, Huntsman DG, Gilks CB, McAlpine JN. (2012). Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Obstet Gynecol 120(2 Pt 1): 235-240
23. Scully RE. (1999). World Health Organization International Classification of tumours. Histological Typing of Ovarian Tumors. Springer: Berlin, Heidelberg, New York, Tokyo
24. Singer G, Kurman RJ, Chang HW, Cho SK, Shih IeM. (2002). Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 160(4): 1223-1228
25. Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P, Panel IRT. (2013). The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol 37(10): 1469-1489
26. Tavassoli FA, Devilee P. (2003). Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press: Lyon, France
27. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF. American Society of Clinical OncologyCollege of American Pathologists. (2013). Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31): 3997-4013